ERBB2 and breast carcinoma: Systemic palbociclib therapy to treat hormone receptor‐positive HER2‐negative breast cancer (once daily for weeks) has unsurprisingly been found to cause hair loss (Ro et al, 2015; Finn et al, 2016).